A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  McKie, Elizabeth A ^a   Reid, Juliet L ^a   Mistry, Prafull C ^a   DeWall, Stephen L ^b   Abberley, Lee ^b   Ambery, Philip D ^a,d   Gil Extremera, Blas ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GSK 1070806; INTERLEUKIN 18; INTERLEUKIN 18 MONOCLONAL ANTIBODY; METFORMIN; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; GSK1070806;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIVERTICULITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERESTHESIA; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NERVE PARALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; MIDDLE AGED; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-18; MALE; METFORMIN; MIDDLE AGED; OBESITY; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84961917325     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150018     Document Type: Article

References (31)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med. 1997; 14: S7-S85.
2. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev. 2012; 249: 239-252. doi: 10.1111/j.1600-065X.2012. 01145.x PMID: 22889226
3. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, et al. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes. 2000; 49: 517-520. PMID: 10868978
4. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001; 52: 119-123. PMID: 11311966
5. Lin S, Wang Y, Sheu W. Increased serum soluble tumor necrosis factor receptor levels are associated with insulin resistance in liver cirrhosis. Metab Clin Exp. 2004; 53: 922-926. PMID: 15254888
6. Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014; 63: 1115-1123. doi: 10.2337/db12-1625 PMID: 24222348
7. López-Bermejo A, Bosch M, Recasens M, Biarnés J, Esteve E, Casamitjana R, et al. Potential role of interleukin-18 in liver disease associated with insulin resistance. Obes Res. 2005; 13: 1925-1931. PMID: 16339124
8. Bosch M, Lopez-Bermejo A, Vendrell J, Musri M, Ricart W, Fernandez-Real J. Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia. 2005; 48: 1841-1843. PMID: 16052331
9. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol. 2005; 117: 152-160. PMID: 16112617
10. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54: 2932-2938. PMID: 16186395
11. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millán JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab. 2004; 89: 806-811. PMID: 14764799
12. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005; 25: 1268-1273. PMID: 15790931
13. Trøseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol. 2010; 9.
14. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002; 5: 551-559. PMID: 12172480
15. Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998; 41: 1241-1248. PMID: 9794114
16. Pickup J, Mattock M, Chusney G, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40: 1286-1292. PMID: 9389420
17. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo J, Naugler W, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007; 6: 386-397. PMID: 17983584
18. Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M. Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-β 1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract. 2009; 83: 190-199. doi: 10.1016/j.diabres.2008.11.018 PMID: 19110334
19. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metab Clin Exp. 2003; 52: 605-608. PMID: 12759891
20. Wong C, Ho A, Tong P, Yeung C, Kong A, Lun S, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol. 2007; 149: 123-131. PMID: 17425653
21. Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanasaki M, et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia. 2007; 50: 867-873. PMID: 17225121
22. Fujita T, Ogihara N, Kamura Y, Satomura A, Fuke Y, Shimizu C, et al. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol. 2012; 49: 111-117. doi: 10.1007/s00592-010-0178-4 PMID: 20186552
23. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104: 1598-1603. PMID: 11581135
24. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195: 245-257. PMID: 11805151
25. Welsh P, Woodward M, Rumley A, MacMahon S, Lowe GD. Does interleukin-18 or tumour necrosis factor-α have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. Cytokine. 2010; 50: 94-98. doi: 10.1016/j.cyto.2009.12.014 PMID: 20096599
26. Hulthe J, McPheat W, Samnegård A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis. 2006; 188: 450-454. PMID: 16405895
27. Yuen C, Chiu C, Chang L, Liou C, Lu C, Youssef AA, et al. Level and value of interleukin-18 after acute ischemic stroke. Circ J. 2007; 71: 1691-1696. PMID: 17965486
28. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, et al. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol. 2005; 25: 1458-1462. PMID: 15860738
29. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, et al. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res. 2007; 27: 3645-3649. PMID: 17972530
30. Mistry P, Reid J, Pouliquen I, McHugh S, Abberley L, DeWall S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int J Clin Pharmacol Ther. 2014; 52: 867-879. doi: 10.5414/CP202087 PMID: 25109413
31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487-1495. PMID: 15161807